Is Shield Therapeutics plc a good investment? Shield Therapeutics plc (STX.L) is currently trading at 3.20 GBX. Market analysts have a consensus price target of 15.67 GBX. This suggests a potential upside from current levels.
Earnings Schedule: Shield Therapeutics plc is expected to release its next earnings report on April 29, 2027. The market consensus estimate for Forward EPS is 0.01.
No, it does not currently pay a dividend.
Shield Therapeutics plc is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
The next earnings date is projected to be April 29, 2027. The company currently has a trailing EPS of -0.01.
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, United Kingdom.
| Split Date | Split Ratio to 1 |
|---|---|
| March 1, 2021 | 1.029 |
| Dec. 16, 2022 | 1.029 |
Community Discussion